Brainstorm Cell Therapeutics Inc. (BCLI): What the weekly performance showing


Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) changes shares on Monday trading session, with a change of 17.36% or $1.47 shares. The trading starts at $8.54 and closed at $8.47 throughout the day. The trading session low price was $8.47 and day high was $10.01 on Monday, June 15. After the session, the Healthcare sector daily volume shifted to 1.62 million while its average volume is 552.56K. In other hand, the BCLI market cap reached to $296.11M. While, its current target price is $9.94 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 17.49% and up 79.10% for month. Its quarterly performance was 120.89% above, while its half year performance is up 155.86%. BCLI yearly performance stood at positive 173.83% and rise 132.24% for year-to-date. Current recommendation for Brainstorm Cell Therapeutics Inc. is 2.00.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. BCLI EPS (TTM) for 12-month is -1.10. EPS for this year is -52.20%, while for the next year its value is -0.70. Its EPS Q/Q reached -18.80%. It has an EPS of -9.40% down for past five years.

Let’s take a look on the analyst recommendations on BCLI for the current month and previous month. For the current month, 2 of 2 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $9.00-$17.50. Average target price for BCLI was reached at $13.50.

The insider ownership moved to 1.40% and institutional holding shifted to 12.30%.

The company posted an EPS (TTM) of -1.10. According to the most recent quarter report on (Jun 2020), 3 analysts estimated an average EPS of -0.26, while -0.23 EPS posted a year ago period. Analyst Estimated EPS for BCLI published in the report was -0.3–0.21 during the same period. Comparing with last year, the average estimated EPS was -0.23 which is higher than -0.32 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for BCLI rise 101.27% for period of 200 days. SMA for 50 days was 54.18% which is showing green signal, while SMA-20 was 34.52%. The moving average value for Brainstorm Cell Therapeutics Inc. (BCLI) is 5.49 and 6.96 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in BCLI stock. On Dec 24, Shah Preetam, EVP, CFO and Treasurer, bought 11,600 trading shares at the cost of $3.96, which valued at 45929.0. On Dec 24, Kern Ralph Dr., COO and Chief Medical Officer, bought 3,000 shares at the cost of $3.88, with total shares of 115,655. On Dec 24, Araya Arturo, Chief Commercial Officer, bought 3,000 shares at the cost of 3.90. After this transaction, Araya Arturo total shares reached to 8,608 which valued at 11700.0.